Clinigen Group Plc (NASDAQ: CLIGF) has recently received a number of price target changes and ratings updates:

  • 9/12/2017 – Clinigen Group Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
  • 9/8/2017 – Clinigen Group Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
  • 8/30/2017 – Clinigen Group Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
  • 8/29/2017 – Clinigen Group Plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
  • 8/22/2017 – Clinigen Group Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $14.00 price target on the stock. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
  • 7/21/2017 – Clinigen Group Plc was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Clinigen Group Plc (NASDAQ:CLIGF) opened at 13.90 on Thursday. Clinigen Group Plc has a one year low of $8.70 and a one year high of $13.90. The company has a market capitalization of $1.60 billion and a P/E ratio of 85.80.

Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.